Treatment for quitting cigarettes and reducing cannabis use
Official title: Randomized Controlled Trial of Varenicline to Treat Tobacco and Cannabis Co-Use (RECLAIM)
Run by Medical University of South Carolina · NCT06883162 · Data updated 2026-11-12
This study tests if a medication called varenicline can help adults who smoke cigarettes and use cannabis quit smoking and cut down on cannabis use, with support from counseling and online resources.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Medical University of South Carolina Academic / other |
| Locations | 1 site (Charleston, South Carolina) |
| Status | Recruiting |
| Started | May 6, 2025 |
| Main results expected | September 1, 2028 |
| Study ends | January 1, 2029 |
| Registry record updated | April 3, 2026 |
| Trial ID | NCT06883162 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older living in South Carolina who smoke at least 5 cigarettes per day and use cannabis regularly.
✕Probably not a fit
Patients with significant medical or psychiatric issues, pregnant individuals, or those using medications for smoking cessation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of varenicline, a medication typically used for smoking cessation, compared to a placebo in adults who co-use cigarettes and cannabis. Participants will receive counseling and access to online treatment modules to support their quit attempts for cigarettes and reduction attempts for cannabis. The study is conducted remotely, requiring no in-person visits, and aims to address the lack of treatment strategies for individuals who use both substances. The research is based on previous findings that highlight the challenges of co-use and the potential benefits of varenicline for both tobacco and cannabis use.
Why it matters
Potential benefit: If successful, this treatment could significantly improve cessation rates for tobacco and reduce cannabis use among co-users.
How similar studies have gone: While varenicline has shown efficacy for tobacco cessation, this specific approach for co-use of tobacco and cannabis is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: 1. Ages 18 and over (no upper age limit) 2. Must smoke at least 5 tobacco cigarettes per day on at least 20 out of the past 30 days for the past 3 months 3. Must express interest in quitting tobacco 4. Must express interest in cannabis reduction and/or cessation 5. Must submit a positive instant-read test for cotinine and cannabis prior to enrollment 6. Must self-report cannabis use (THC-dominant products) on at 3 days per week out of the past 30 days 7. Must be willing to take varenicline or placebo for 12 weeks 8. Must reside in South Carolina Exclusion criteria: 1. Any significant or acutely unstable medical, psychiatric, or substance use problem (including clinically significant disorders) that would contraindicate research, interfere with safety, compromise data integrity, or preclude consistent study participation 2. Pregnant or trying to become pregnant 3. Use of medications with smoking cessation efficacy 4. Regular use of e-cigarettes or other tobacco products (\<10 days in the past month)
Where it's running
-
Medical University of South Carolina - Charleston
Charleston, South Carolina, United States Recruiting
Study contacts
- Principal investigator: Erin Mcclure — Medical University of South Carolina
- Study coordinator: Erin Mcclure
- Email: mccluree@musc.edu
- Phone: 843-792-7192
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Brain imaging to predict teens' response to cannabis treatment
This project will test whether teens' brain activity during a learning task can predict how well 14–17-year-olds do in a 10-week virtual reward program to reduce cannabis use.
-
Oral saliva testing to detect recent cannabis use in young adults.
This project will test whether at-home saliva tests can detect recent cannabis use in 18-to-30-year-olds who use cannabis at least once a week.
-
Using Cannabidiol to Help People Quit Smoking
This study is testing if taking cannabidiol (CBD) can help people who smoke more than 10 cigarettes a day quit smoking and feel better during withdrawal.
-
Investigating cognitive function in psychosis patients and cannabis users
This study is testing how taking a break from cannabis for 28 days affects thinking skills and brain activity in people with psychosis and those who use cannabis but don’t have mental health issues.
-
Can tACS modulate motivation and reward signals in cannabis use disorder and depression
We’re testing whether a gentle brain stimulation method (tACS) can boost motivation and reward responses in adults with cannabis use and/or depression to see if it helps with anhedonia.
-
Sex differences in how cannabis affects people who regularly use it
This Phase 2 trial tests whether men and women who use cannabis several days a week respond differently to THC versus placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.